Patent ID: 9011853
Filing Date: 2015-04-21
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method for reducing inflammation in a human subject, comprising administering to the subject two or more pharmaceutical dosage units, each dosage unit comprising a dose of 3 mg/kg to 20 mg/kg of a fusion protein comprising a B7-H4 polypeptide comprising the IgV domain of SEQ ID NO:63 or SEQ ID NO:64 fused to a second polypeptide or fused to a linker peptide fused to a second polypeptide, wherein at least two of the dosage units are administered at least two days apart and within two weeks, to increase the ratio of regulatory T cells (Tregs) relative to total CD4+ cells in the subject and reduce inflammation in the subject for at least a week post administration.